Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691859 · ClinicalTrials.gov registry record · Phase 3
MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 347
- Enrollment target
NCT01691859 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 347 participants.
The verdict
NCT01691859, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 347 participants
- Enrollment target
Study Summary
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed.
Interventions
- DRUG Mepolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2012-09-28 |
| Est. Completion | 2017-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691859
The ClinicalTrials.gov registry entry for NCT01691859 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mepolizumab is the first listed.
NCT01691859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01691859 about?
NCT01691859 is a clinical study titled "MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects". This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be revi...
What is the current status of trial NCT01691859?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 347 participants. The study started on 2012-09-28. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT01691859?
The interventions under investigation include: Mepolizumab (DRUG).
Who is sponsoring clinical trial NCT01691859?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.